SRTS — Sensus Healthcare, Inc.

Sensus Healthcare, Inc. (SRTS) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $3.4 million, down from $8.3 million year-over-year, primarily due to the absence of sales to the company's largest customer.
• Gross Profit: $1.0 million, with a gross margin of 29.2%, compared to 52.2% in the prior year, reflecting a shift in product mix and lower average selling prices.
• Operating Expenses: General and administrative expenses decreased to $2.0 million; selling and marketing expenses fell to $1.7 million; R&D expenses decreased to $1.6 million.
• Net Loss: $2.6 million, or $0.16 per share, consistent with the prior-year period.
• Cash Position: $18.3 million in cash with no debt, and inventory increased to $16.5 million.

2. Strategic Updates and Business Highlights

• CPT Code Implementation: The introduction of dedicated CPT codes for superficial radiotherapy (SRT) as of January 1, 2026, is expected to enhance reimbursement clarity and drive customer adoption.
• Customer Diversification: The company shipped 14 SRT systems in Q1, including 10 direct sales and 4 under rental agreements, aiming to reduce historical customer concentration.
• Recurring Revenue Focus: The introduction of SensusLink aims to enhance workflow and create a scalable recurring revenue model tied to treatment activities.
• Commercial Expansion: Sensus Healthcare Financial Services was launched to provide flexible financing options for customers, improving conversion rates.

3. Forward Guidance and Outlook

• Revenue Expectations: Q2 revenue is expected to be higher than Q1, with continued growth anticipated throughout 2026 as the sales pipeline strengthens.
• Profitability Goal: The company aims to achieve full-year profitability by leveraging improved reimbursement, a diversified customer base, and expanding recurring revenue streams.

4. Challenges and Points of Concern

• Customer Concentration: The absence of sales to the largest customer, which previously accounted for significant revenue, poses a risk to revenue stability.
• Revenue Decline: Year-over-year revenue decreased significantly, raising concerns about the transition to a more diversified customer base.
• Gross Margin Pressure: The decline in gross margin due to product mix and lower average selling prices may affect profitability in the short term.

5. Notable Q&A Insights

• Customer Return Potential: Management indicated that the largest customer not purchasing in Q1 is viewed as potential upside if they return, but they are not included in the current financial model.
• Sales Cycle Impact: The new CPT codes have led to increased interest and inquiries, with expectations of shorter sales cycles as practices gain confidence in reimbursement.
• Pipeline Development: The sales team is optimistic about converting leads generated from recent dermatology conferences into sales, with a focus on education and awareness of the new reimbursement codes.
• Recurring Revenue Timeline: Management believes that as education about SRT expands, adoption will increase, leading to a more predictable revenue stream, particularly through the SensusLink software.

Overall, Sensus Healthcare is navigating a transitional phase with a focus on leveraging new reimbursement codes to drive customer adoption and recurring revenue, while also addressing challenges related to customer concentration and revenue decline.